Abstract 1496P
Background
Determining when to initiate renal replacement therapy (RRT) in cancer patients with acute kidney injury (AKI) can pose a considerable challenge, particularly for those with limited treatment options for cancer and a short life expectancy. This study aims to explore the predictors of short-term mortality among cancer patients undergoing hemodialysis following AKI.
Methods
Between January 2014 and April 2023, this retrospective study included 139 hospitalized patients with various cancers who underwent hemodialysis for AKI in Hacettepe University Oncology Hospital. Clinical and laboratory features, comorbidities, and survival outcomes were collected. Predictors of 30-day mortality after initiation of hemodialysis were evaluated.
Results
Median age was 64 and 39% were females. ECOG performance score was 3-4 in 48%. Median Charlson comorbidity index was 8. Among the patients, 26% had gastrointestinal cancers and 23% had lung cancer. Notably, the etiology of AKI was prerenal-renal in 93% of the cases, with 45% of AKI instances occurring during hospitalization. 111 patients (80%) died within 30 days after the first hemodialysis session. In multivariate analysis, serum albumin less than 2.5 g/dl (OR: 3.14, 95% CI; 1.23-8.04, p=0.017), presence of sepsis (OR: 3.50, 95% CI; 1.34-9.10, p=0.010), prerenal-renal AKI (compared to postrenal AKI) (OR: 6.06, 95% CI 1.38-26.56, p=0.017) were associated with higher 30-day mortality. Patients with none of these risk factors had 33% 30-day mortality while those with all the identified risk factors had significantly higher rate of 93% (p<0.001).
Conclusions
In this study, patients with sepsis, pre-renal or renal AKI, and low albumin levels had higher early mortality rates after hemodialysis. Identifying AKI patients unlikely to benefit from RRT may assist clinicians in making informed decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10